SCHEMBL24310791

SCHEMBL24310791

Cc1cccc(C)c1-c1cc(Oc2cc(Cl)cc(C(=O)O)c2)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.38
▸ FGFR1 P11362 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ ENPP2 Q13822 1/20 0.37
▸ ACLY P53396 1/20 0.37
▸ GPR119 Q8TDV5 4/20 0.36
▸ TSHR P16473 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CCR2 P41597 1/20 0.35
▸ AURKA O14965 2/20 0.35
▸ AURKB Q96GD4 2/20 0.35
▸ F2 P00734 1/20 0.34
▸ F10 P00742 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ HTR1A P08908 1/20 0.33
▸ HTR7 P34969 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.33
▸ PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567535 1.00 EGFR (0.38) EGFRFGFR1KDRENPP2ACLY
SCHEMBL29566644 0.92 FGFR1 (0.39) EGFRFGFR1KDRGPR119AURKA
SCHEMBL26874925 0.92 FGFR1 (0.39) EGFRFGFR1KDRGPR119AURKA
SCHEMBL26810134 0.91 PTGDR2 (0.41) EGFRFGFR1KDRGPR119CYP3A4
SCHEMBL29566838 0.90 GFER (0.39) EGFRFGFR1KDRTSHRSMN1; SMN2
SCHEMBL24310039 0.90 GFER (0.39) EGFRFGFR1KDRTSHRSMN1; SMN2
SCHEMBL26810141 0.90 GPR119 (0.38) EGFRFGFR1KDRGPR119AURKA
SCHEMBL26810137 0.89 NR1H2 (0.39) EGFRFGFR1KDRGPR119CCR2
SCHEMBL26810139 0.89 CCR2 (0.37) EGFRFGFR1KDRGPR119CCR2
SCHEMBL26810132 0.89 EGFR (0.36) EGFRFGFR1KDRGPR119CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B EGFR 818/4885FGFR1 2391/4885KDR 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback